fashion -WSS

fashion

author：comprehensive 2025-09-30 01:01:56 - browse：8943

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Smaller biotechs seek to piggyback on weight loss drug boom

hotspot

WSS

Think you might have Covid

New brain studies show LSD's effects on the brain in full color

Think you might have Covid

How digital therapeutics firms are pivoting after Pear's bankruptcy

Readout Newsletter: Merck, J&J, and long Covid

NIH director takes cautious approach to Biden drug pricing priority

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Summit: The economic case for universal basic health care

Walensky prepares to leave CDC — and Congress — behind

Dewpoint Therapeutics lays off staff after losing partnerships

Apple is now the first public company to be valued at $3 trillion

Research misconduct: Proposed new rules face resistance

Peter Hotez and the public health issue of online harassment

Why a market frenzy over new weight loss drugs defies logic

BioMarin wins approval for gene therapy to treat hemophilia A

Roche acquires Telavant from Roivant, adding experimental IBD treatment

knowledge

Francis Collins on trust in science and how Covid communications failed

Eli Lilly, Pfizer, and others want in on the online prescription market

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

How digital therapeutics firms are pivoting after Pear's bankruptcy

eGenesis tests gene

NIH director takes cautious approach to Biden drug pricing priority

hotspot

leisure time

explore

hotspot